Atlas Trials

A Study to Evaluate the Safety, Immunogenicity and Efficacy of GlaxoSmithKline (GSK) Biologicals' Candidate Malaria Vaccine RTS,S/AS02A, When Administered to Children Aged 1 to 4 Years Living in a Malaria-endemic Region of Mozambique.

Clinical trial NCT00197041 · COMPLETED

Trial details

NCT number
NCT00197041
Sponsor
GlaxoSmithKline
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Malaria
Start date
2003-07-01
Primary completion
2005-04-01
Enrollment
2022

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.